Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: A cost-effectiveness analysis

Hepatology

Volumn 55, Issue 4, 2012, Pages 1164-1171

  Bajaj, Jasmohan S ^a,b   Pinkerton, Steven D ^b   Sanyal, Arun J ^a   Heuman, Douglas M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTULOSE; RIFAXIMIN;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; FOLLOW UP; HEALTH CARE COST; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; INHIBITORY CONTROL TEST; MAJOR CLINICAL STUDY; MINIMAL HEPATIC ENCEPHALOPATHY; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOMETRY; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; TRAFFIC ACCIDENT; TREATMENT INDICATION;

ACCIDENTS, TRAFFIC; AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LACTULOSE; LIVER CIRRHOSIS; MARKOV CHAINS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMETRICS; RIFAMYCINS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84859133780     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25507     Document Type: Article

References (39)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. HEPATOLOGY 2002; 35: 716-721.
2. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-535.
3. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J Hepatol 2007; 47: 67-73.
4. Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986; 3: 75-82.
5. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 2718-2723.
6. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007; 102: 1903-1909.
7. Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. HEPATOLOGY 2004; 39: 739-745.
8. Watanabe A, Tuchida T, Yata Y, Kuwabara Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis 1995; 10: 239-248.
9. Bajaj JS, Hafeezullah M, Hoffmann RG, Varma RR, Franco J, Binion DG, et al. Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. HEPATOLOGY 2008; 47: 596-604.
10. Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45: 1549-1552.
11. Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol 2005; 42 (Suppl): S45-53.
12. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011; 33: 739-747.
13. Mullen K, Ferenci P, Bass NM, Leevy CB. An algorithm for the management of hepatic encephalopathy. Semin Liver Dis 2007; 27: 32-48.
14. Bajaj JS, Etemadian A, Hafeezullah M, Saeian K. Testing for minimal hepatic encephalopathy in the United States: an AASLD survey. HEPATOLOGY 2007; 45: 833-834.
15. Bajaj JS, Hafeezullah M, Franco J, Varma RR, Hoffmann RG, Knox JF, et al. Inhibitory control test for the diagnosis of minimal hepatic encephalopathy. Gastroenterology 2008; 135: 1591-1600 e1591.
16. Amodio P, Ridola L, Schiff S, Montagnese S, Pasquale C, Nardelli S, et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology 2009; 139: 510-518, 518 e511-512.
17. Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. HEPATOLOGY 2009; 50: 1175-1183.
18. Gad YZ, Zaher AA, Moussa NH, El-Desoky AE, Al-Adarosy HA. Screening for minimal hepatic encephalopathy in asymptomatic drivers with liver cirrhosis. Arab J Gastroenterol 2011; 12: 58-61.
19. Sharma BR. Road traffic injuries: a major global public health crisis. Public Health 2008; 122: 1399-1406.
20. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. HEPATOLOGY 2007; 45: 549-559.
21. Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. HEPATOLOGY 1997; 26: 1410-1414.
22. Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997; 11: 165-170.
23. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-316.
24. Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011; 140: 478-487 e471.
25. Bajaj JS, Riggio O. Drug therapy: rifaximin. HEPATOLOGY 2011; 52: 1484-1488.
26. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford, UK: Oxford University Press; 1996.
27. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther 2007; 26: 1147-1161.
28. Rikkers L, Jenko P, Rudman D, Freides D. Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology 1978; 75: 462-469.
29. Riggio O, Ridola L, Pasquale C, Nardelli S, Pentassuglio I, Moscucci F, et al. Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2010; 9: 181-183.
30. Red Book. 2007 ed. Montvale, NJ: Thomson Healthcare Inc., 2007.
31. Kalaitzakis E, Bjornsson E. Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health-related quality of life. HEPATOLOGY 2007; 46: 949-950; author reply 951.
32. Kalaitzakis E, Simren M, Olsson R, Henfridsson P, Hugosson I, Bengtsson M, et al. Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. Scand J Gastroenterol 2006; 41: 1464-1472.
33. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010; 31: 1012-1017.
34. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-773.
35. Iduru S, Mullen KD. The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy. Gastroenterology 2008; 135: 1455-1456.
36. Conn H. Hepatic Encephalopathy: Management with Lactulose and Related Carbohydrates. East Lansing, MI: Medi-Ed Press; 1988.
37. Bajaj JS, Saeian K, Hafeezullah M, Hoffmann RG, Hammeke TA. Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clin Gastroenterol Hepatol 2008; 6: 1135-1139; quiz 1065.
38. Bajaj JS, Thacker LR, Heuman DM, Gibson DP, Sterling RK, Todd Stravitz R, et al. Driving simulation can improve insight into impaired driving skills in cirrhosis. Dig Dis Sci 2011 [Epub ahead of print].
39. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081.